HPGC(SH:600664) Ge Long Hui A P P·2025-10-20 08:56Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) has received the drug registration certificate for Oseltamivir Phosphate Dry Suspension from the National Medical Products Administration, indicating a significant advancement in its product portfolio [1] Group 1: Company Developments - Harbin Pharmaceutical Group's subsidiary, Harbin Pharmaceutical Group Pharmaceutical Sixth Factory, has been granted the drug registration certificate with the number 2025S03139 for Oseltamivir Phosphate Dry Suspension [1] - The approved product is intended for the treatment of influenza types A and B in patients aged 2 weeks and older, and for the prevention of influenza types A and B in individuals aged 1 year and older [1] Group 2: Product Information - Oseltamivir Phosphate is a potent selective neuraminidase inhibitor that effectively inhibits the neuraminidase activity of influenza viruses, thereby reducing the spread of the virus from infected cells [1] - The active metabolite of Oseltamivir Phosphate, Oseltamivir Carboxylate, plays a crucial role in its antiviral efficacy [1]